Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer

Background and Objectives: Standard treatment in metastatic breast cancer with positive estrogen receptors and negative HER2neu is represented by CDK4 inhibitors combined with aromatase inhibitors or fulvestrant. Palliative radiotherapy is indicated for symptoms or local–regional control. Multiple p...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Journal of Mind and Medical Sciences
المؤلفون الرئيسيون: Laura-Florentina Rebegea, Dorel Firescu, Oana-Gabriela Trifanescu, Roxana-Andreea Rahnea-Nita, Liviu Bilteanu, Mihaela Dumitru, Florentina Lacatus, Gabriela Rahnea-Nita
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2025-05-01
الموضوعات:
CDK4/6 inhibitors
toxicity
metastatic breast cancer
الوصول للمادة أونلاين:https://www.mdpi.com/2392-7674/12/1/33

الانترنت

https://www.mdpi.com/2392-7674/12/1/33

مواد مشابهة